Skip to main content
Health & Medicine

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

| Source: Nature medicine

Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant ICIs (n = 735), BRAF and MEK inhibitors (BRAF/MEKis; n = 119) or ICI plus any targeted therapy (ICI + TT; n = 184) from 26 in

Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant ICIs (n = 735), BRAF and MEK inhibitors (BRAF/MEKis; n = 119) or ICI plus any targeted therapy (ICI + TT; n = 184) from 26 international sites in both trial (755, 72.7%) and nontrial (283, 27.3%) settings. ICI regimens included anti-programmed cell death protein 1 (PD-1) alone (PD-1 alone; n = 242) and anti-PD-1 plus other immuno-oncology agent(s) (PD-1 + IO; n = 489). Outcomes included major pathological response (MPR), recurrence-free survival (RFS) and overall survival (OS). An MPR was achieved in 57.8% of patients with ICIs, 51.4% with BRAF/MEKis and 44.6% with ICI + TT. PD-1 + IO elicited higher MPR rates than PD-1 alone (61.4% versus 49.5%). The 5-year RFS rate was 61.0% with PD-1 alone, 73.9% with PD-1 + IO, 37.4% with BRAF/MEKis and 76.4% with ICI + TT; the 5-year OS rates were 83.3%, 87.5%, 69.8% and 83.9%, respectively. ICI-treated patients with MPR had 5-year OS rates of 98.8% with PD-1 alone and 97.9% with PD-1 + IO and gained no benefit from continuing ICIs into the adjuvant setting. Neoadjuvant ICIs were active in BRAF-mutant melanoma (MPR, 46.3%), acral melanoma (38.1%), in-transit metastases (66.7%) and oligometastases (41.2%), although subgroup sizes and relative effectiveness varied. Survival outcomes were excellent with neoadjuvant ICIs, particularly in patients achieving MPR, but poor with BRAF/MEKis and mixed with ICI + TT. Predictive biomarker-driven trials, effective adjuvant strategies and subgroup-specific research are needed for nonresponders.

Read the original source →

Related Topics

Related Stories

Health & Medicine

Distinct nanoscale architectures of GABAergic inhibitory synapses predict diverse synaptic output.

GABAergic synaptic inhibition is heterogenous across neuronal compartments, and plays a critical role in shaping local, cellular, and circuit excitability. In pyramidal neurons, inhibition is mediated by GABA A receptors (GABA A Rs) clustered at the inhibitory postsynaptic domain (iPSD). Synaptic strength depends not only on the number of GABA A Rs within the iPSD, but also on their precise nanoscale organization into discrete subsynaptic domains (SSDs). These SSDs often align with presynaptic G

Continue reading
Health & Medicine

Leptin Receptor + cells create a perisinusoidal niche for thrombopoiesis in the bone marrow by synthesizing CXCL14.

Leptin Receptor-expressing (LepR + ) stromal cells in the bone marrow are a critical source of growth factors for the maintenance of hematopoietic stem cells (HSCs) and most restricted hematopoietic progenitors. An important unresolved question is whether they also regulate terminal differentiation in some hematopoietic cells. We found that bone marrow LepR + cells promote thrombopoiesis by synthesizing the chemokine CXCL14. Cxcl14 -expressing LepR + cells extend fine processes that wrap around

Continue reading
Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading